Table 3. Costs, health effects, and cost-effectiveness of different screening strategies.
| Interventions | Costs (millions) | Effectiveness | Cost-effectiveness (thousands per DALY averted) | |||
| Patients | Program | Total (95% CI) | DALYs averted (95% CI) | Average (95% CI) | Incremental (95% CI) | |
| Uni. OAE+AABR | 38 | 236 | 274 (163–460) | 7,710 (6,910–8,520) | 36 (20–63) | 163 (90–317) |
| Uni. OAE | 44 | 164 | 208 (118–306) | 7,310 (6,380–8,240) | 28 (15–42) | 38 (22–58) |
| Select. OAE+AABR | 7.5 | 65 | 72 (53–98) | 3,780 (3,390–4,170) | 19 (13–27) | 127 (94–180) |
| Select. OAE | 7.5 | 39 | 47 (33–62) | 3,580 (3,130–4,040) | 13 (8–17) | 13 (8–17) |
| No screening | 0 | 0 | 0 | 0 | NA | NA |
Note: Uni.OAE+AABR = universal strategy using OAE plus AABR; Uni.OAE = universal strategy using OAE; Select.OAE+AABR = targeted strategy using OAE plus AABR; Select.OAE = targeted strategy using OAE.